One Year of Qubigen: From Federated AI Vision to Scalable Drug Design Reality

As Qubigen approaches the end of 2025, we mark an important milestone: our first year of operation. In just over twelve months, Qubigen has evolved from an innovative idea into a validated, capital-efficient drug design platform, demonstrating that secure, Federated AI can deliver real scientific progress, commercial traction, and scalable value across the life sciences ecosystem. This first year has been defined by three converging forces: strong technical performance, global engagement, and a business model designed to scale.

Proving the Technology Where It Matters

At the heart of Qubigen is FedAIDD, our patented Federated AI Drug Design platform. Over the past year, we moved well beyond theory, showing that federated learning, when combined with generative AI, quantum chemistry, synthetic feasibility analysis, and ADMET prediction, can outperform traditional centralized approaches while preserving data sovereignty.

In the past year, Qubigen has successfully:

• Completed benchmark studies showing Federated AI can generate novel molecules with potency comparable to or greater than those developed using conventional medchem methods or centralized AI models, and with the potential to grow beyond that of a single centralized repository in scope, scale and diversity of assay types.

• Deployed node-level controls within federated workflows, enabling fine-grained optimization of physicochemical and ADMET properties, as well as binding profile, without exposing sensitive data.

• Demonstrated that negative experimental data, such as valuable insights from failed chemical reactions inaccessible by conventional AI, can dramatically improve predictive performance when trained securely via federated methods.

• Applied FedAIDD to real client datasets, reproducing known SAR in a matter of weeks rather than years, replicating blind holdback compounds with close to 100% accuracy, and generating new candidates with favorable drug-like properties.

  
  

These results have validated not only our technology, but have also demonstrated that federated AI can outperform centralized approaches and conventional methods while preserving data privacy and ownership.

Building Momentum Through Global Engagement

Alongside technical delivery, Qubigen spent its first year actively engaging the global biotech and research community.

Throughout 2025, Qubigen leadership presented and participated at major international and regional forums, including the BIO 25 International Convention, AusBiotech, Discovery on Target, academic workshops, and institutional seminars, sharing a consistent message: enhanced drug design is now possible without compromising data security.

These engagements translated into the establishment of formal research frameworks with leading Australian institutions, including the University of Melbourne, the University of Adelaide and QIMR Berghofer, an enabling step toward secure application of AI-driven molecular design to proprietary datasets while ensuring full protection of partner data and IP.

Alongside academia, Qubigen has worked closely with biotechnology and pharmaceutical partners to advance early-stage drug programs. Our partnership with Rio Pharmaceuticals marked a significant step into AI-enhanced therapeutics for neurological disease, combining federated learning, quantum chemistry, and ADMET-aware design to generate novel small-molecule candidates optimized for brain penetration. In oncology, collaborations with SyzOnc and our ongoing participation in the TBXT Challenge demonstrated Qubigen’s ability to operate at the frontier of drug discovery, addressing complex tumor biology, completely novel oncoproteins, and transcription factors long considered beyond the reach of small-molecule therapeutics.

Qubigen Partners

As Qubigen enters 2026, this momentum continues with our upcoming participation at JPM Week in San Francisco, where we will be meeting with investors, strategic partners, and industry leaders to discuss the next phase of growth and partnership.

A Model Built to Scale Efficiently

Qubigen’s progress is not accidental; it follows from our Federated AI platform, designed to scale better than centralized AI competitors.

Our federated approach means each new pilot amplifies platform value, without Qubigen seeing or even moving client data or requiring massive infrastructure expansion or prohibitive data acquisition. As a result, Qubigen reaches meaningful milestones quickly, increasing its platform value using only a fraction of the capital that centralized approaches demand. With Qubigen's patented technology, we're poised to scale our projects from 20+ to 200, train AI Engines and provide commercializable IP for a small fraction of the price of competitors, who would need to invest billions in data acquisition to achieve comparable performance [1].

This capital efficiency, combined with early technical validation, positions Qubigen as a highly leveraged growth opportunity for investors, offering an outsized return profile without the typical infrastructure-heavy risk.

A Clear Advantage for CROs

Qubigen’s platform is equally transformative for Contract Research Organizations (CROs).

Rather than building expensive in-house AI teams, limited to internal data, FedAIDD integrates directly into existing workflows, securely training private, high-performing AI Engines leveraging curated, multi-modal data sources with diverse areas of competence – adding richness without manually combining data, and without client data ever leaving their environment.

For CROs, this means:

• Faster design–make–test cycles, compressing SAR timelines from years to months

• Margin expansion of more than 2.5x via higher project throughput and smarter resource allocation

• Stronger client retention through differentiated, AI-enabled discovery capabilities

  
  

With patented data-cleansing technology, low compute overhead, and seamless operational integration, Qubigen enables CROs to deliver faster, smarter, and more profitable discovery programs, strengthening their competitive moat in an increasingly AI-driven industry.

Looking Ahead

One year in, Qubigen has demonstrated that federated AI is not only viable, it is inevitable, building momentum across industry and academic communities. As we head into JPM Week and beyond, Qubigen remains focused on scaling partnerships, expanding pilots, and continuing to turn secure data into real therapeutic impact. The foundations are laid. The flywheel is turning. And the future of AI-accelerated drug design is federated.

References:

1. Bourne, C. Pharma at an inflection point: Where capital, technology and geography are reshaping drug development between 2024 and 2025, https://www.foundernest.com/insights/pharma-at-an-inflection-point (2025)